Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Fineline Cube Aug 5, 2026
Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Fineline Cube Aug 5, 2026
Company

Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization

Fineline Cube Jan 12, 2023

Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several...

Company Drug Legal / IP

MSD China to Take Legal Action Against Market Infringement of Molnupiravir

Fineline Cube Jan 12, 2023

Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...

Company Deals

Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio

Fineline Cube Jan 12, 2023

Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi...

Company Drug

Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution

Fineline Cube Jan 12, 2023

China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...

Company Deals

Bioantibody Bio Raises RMB 100 Million in Series A Funding Round

Fineline Cube Jan 12, 2023

Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly...

Company Deals

Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests

Fineline Cube Jan 12, 2023

China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with...

Company Drug

CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA

Fineline Cube Jan 12, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Policy / Regulatory

China’s Dental Implant VBP Tender Results in Significant Price Cuts

Fineline Cube Jan 12, 2023

The results of the dental implant system-focused volume-based procurement (VBP) tender held in Sichuan have...

Company Drug

Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC

Fineline Cube Jan 12, 2023

Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...

Company Deals

MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor

Fineline Cube Jan 12, 2023

MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co.,...

Company Drug

Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC

Fineline Cube Jan 12, 2023

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...

Company

BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit

Fineline Cube Jan 12, 2023

China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...

Company Deals

Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics

Fineline Cube Jan 11, 2023

China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...

Company Drug

Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone

Fineline Cube Jan 11, 2023

US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...

Company Deals

HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges

Fineline Cube Jan 11, 2023

The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,...

Company Drug

Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors

Fineline Cube Jan 11, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...

Company Drug

Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Company Drug

HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH

Fineline Cube Jan 11, 2023

Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a...

Drug

MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules

Fineline Cube Jan 11, 2023

Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...

Company Drug

Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA

Fineline Cube Jan 11, 2023

China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...

Posts pagination

1 … 612 613 614 … 703

Recent updates

  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
  • Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections
  • Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age
  • Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Company Drug

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Company Drug

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.